Progyny (PGNY) news
Recent news
Progyny Q2 adjusted EPS USD 0.55 vs. IBES estimate USD 0.34
AInvest Wire · Aug 6, 2026Progyne outlook Q3 adjusted EPS USD 0.5-0.52
Progyny (PGNY) has provided updated financial guidance for the third quarter of 2026, projecting adjusted EPS range of $0.50 to $0.52. This outlook reflects the company’s expectations for continued strong performance following its first-quarter 2026 results, where it reported adjusted EPS of $0.50…
AInvest Wire · Aug 6, 2026Progyny Inc: Leerink Partners raises target price to $38 from $30
Leerink Partners has raised its price target for Progyny Inc (NASDAQ: PGNX) to $38 from $30, reflecting a positive reassessment of the company’s outlook [1]. The adjustment follows recent developments in the fertility care sector and Progyny’s strategic positioning within it. The firm’s updated…
AInvest Wire · Jul 22, 2026Progyny Inc: Truist Securities raises target price to $33 from $30
AInvest Wire · Jun 22, 2026ImportantProgyny up 6% on insider buys
Progyny up 6% on insider buys Progyny Inc. (PGNY), a healthcare services company specializing in fertility benefits, experienced a notable surge of 6% in its stock price on November 14, 2024 [1]. This uptick can be attributed to a series of insider purchases made by key executives and prominent…
AInvest Wire · Dec 27, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.